Enzo (ENZ): רווח למניה בשנים עשר החודשים האחרונים

The use of cloud IT solutions minimizes infrastructure risks, and the GURU.Markets terminal displays the rolling annual earnings per share, where -0.41 captures the current state of the parameter for Enzo Biochem, Inc. (ENZ). Business stability relies on internal reagent synthesis and strict quality control. An extensive array of diagnostic patents and licensing rights for unique medical methodologies generates additional income.

The operational efficiency of molecular biologists and compliance specialists at Enzo Biochem, Inc. (ENZ) directly impacts the net income per share TTM. This indicator reflects the issuer's aggregate income over a rolling year, distributed across the total volume of shares. The metric demonstrates the actual equity return, adjusted for the impact of issuance. Growth in this figure above the weighted average cost of capital (WACC) confirms value creation. The stability of this trend characterizes the fundamental resilience of the business.